EL7.AI
StocksMedium•19 November 2026•
3 min read

MDB Fee Income Rises 96% to $4.2 Million in First Nine Months

Key Facts

1Fee income rose 96% to $4.2 million for the nine months ended September 30, 2026, from $2.1 million a year earlier.
2Fee income in the SEC report was about $3.3 million, up 54% from $2.1 million in the year-earlier period.
3Net loss was $32.499 million, compared with $19.508 million a year earlier.
4Cash was $8.315 million, and the company used $6.697 million in its operating activities during the nine months.

MDB Capital Holdings said in a business update issued on November 17 that fee income rose 96% to $4.2 million for the nine months ended September 30, 2026, compared with $2.1 million a year earlier. That growth put fees at the forefront of the company’s reported developments for the period, alongside updates on its portfolio companies. But the report filed with the U.S. Securities and Exchange Commission presents a different financial figure: fee income was $3.306 million, up 54% from $2.140 million in the year-earlier period. The company attributed the increase in the report to the completion of larger investment-banking transactions, particularly in the first half of 2026. It also recorded $333,000 in investment-banking fee income in the third quarter, after closing no offerings in the corresponding quarter of 2025.

The report indicates that higher fee income did not prevent net losses from widening, reaching $32.499 million for the nine months, compared with $19.508 million a year earlier. The company’s loss from its share of an equity-method investment rose to $13.225 million, from $3.048 million in the same period of 2025. The company said the increase reflected its share of losses at eXoZymes and an impairment loss on the investment. It also recorded $5.9 million in unrealized losses on securities, compared with $2.4 million a year earlier, attributing them to declines in the market values of securities and warrants. According to the company’s statement, operating expenses were flat compared with the same period a year earlier and the previous quarter.

Balance-sheet data show liquidity came under pressure during the period: cash and cash equivalents stood at $8.315 million on September 30, 2026. The company used $6.697 million in cash in its operating activities during the nine months ended on that date. Working capital was $9.9 million, down $5.7 million from $15.6 million on September 30, 2025. The company attributed the decline in working capital mainly to cash used to fund operations. In another revenue line, intellectual-property services and self-clearing fee income rose to $669,000 for the nine months, from $469,000 a year earlier.

Among its portfolio companies, MDB said Public Ventures is seeking strategic and capital partners to expand its self-clearing platform. The options cited by the company include the possibility of launching the platform independently of MDB. PatentVest, in turn, is seeking funding to expand its customer base and increase marketing spending, ahead of a possible transition to an independent company in 2027. The statement set no deadline for this transition, presenting it as a possibility tied to the company’s plan. MDB also said its board is reviewing potential structures for sharing any value generated by the businesses with shareholders when key milestones are reached.

At eXoZymes, the company selected Curia as its first commercial-scale manufacturing partner, with the aim of supporting technology transfer and expanding NCT production toward commercial manufacturing. Paulex Bio announced the registration of a first-in-human Phase 1/2a trial of its experimental oral drug PAL-119. The trial aims to assess the drug’s safety and tolerability and explore the potential for beta-cell expansion. These initiatives were among the operational updates MDB included with its financial results, while the statement gave no additional timeline for completing the technology transfer or for trial results. Chief Executive Officer and Co-Founder Christopher Marlett was scheduled to lead a webinar on November 17 at 4:30 p.m. Eastern Time to present a third-quarter update.

Open on chart